Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Cost-minimization Analysis of Drugs Used in the Treatment of Asthma and COPD Diseases in India

Author(s): Billu Payal, Anoop Kumar* and Harsh Saxena

Volume 16, Issue 1, 2021

Published on: 13 August, 2020

Page: [83 - 88] Pages: 6

DOI: 10.2174/1574885515999200813193250

Price: $65

Abstract

Background: Asthma and Chronic Obstructive Pulmonary Diseases (COPD) are well known respiratory diseases affecting millions of people in India. In the market, various branded generics, as well as generic drugs, are available for their treatment and how much cost will be saved by utilizing generic medicine is still unclear among physicians. Thus, the main aim of the current investigation was to perform cost-minimization analysis of generic versus branded generic (high and low expensive) drugs and branded generic (high expensive) versus branded generic (least expensive) used in the Department of Pulmonary Medicine of Era Medical University, Lucknow for the treatment of asthma and COPD.

Methods: The current index of medical stores (CIMS) was referred for the cost of branded drugs, whereas the cost of generic drugs was taken from the Jan Aushadi scheme of India 2016. The percentage of cost variation, particularly to Asthma and COPD regimens on substituting available generic drugs, was calculated using standard formula and costs were presented in Indian Rupees (as of 2019).

Results: The maximum cost variation was found between the respules budesonide high expensive branded generic versus least expensive branded generic drugs and generic versus high expensive branded generic. In combination, the maximum cost variation was observed in the montelukast and levocetirizine combination.

Conclusion: In conclusion, this study inferred that substituting generic antiasthmatics and COPD drugs can bring potential cost savings in patients.

Keywords: Asthma, chronic obstructive pulmonary disease, cost minimization analysis, pharmacoeconomic, generic drugs, levocetirizine.

« Previous Next »
Graphical Abstract

[1]
Donner CF. Conference:” COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future”, Venice, April 21-22, 2010: long summaries. Multidiscip Respir Med 2010; 5(2): 104.
[http://dx.doi.org/10.1186/2049-6958-5-2-104]
[2]
Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 2nd ed. Sheffield: European Respiratory Society 2017; p. 7.
[3]
Rajagopal TV, Kant S, Verma SK, et al. Aspergillus sensitization in bronchial asthma: A separate phenotype. Allergy Asthma Proc 2020; 41(1): e26-32.
[http://dx.doi.org/10.2500/aap.2020.41.190008] [PMID: 31888791]
[4]
Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19(1): 182-91.
[http://dx.doi.org/10.1183/09031936.02.00283202] [PMID: 11843317]
[5]
Barnes PJ, Drazen JM, Rennard SI, Thomson NC, Eds. Asthma and COPD: basic mechanisms and clinical management. Elsevier 2009.
[6]
Kashyap A, Balaji MN, Chhabra M, Rashid M, Muragundi PM. Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India. Expert Rev Pharmacoecon Outcomes Res 2020; 20(4): 355-61.
[http://dx.doi.org/10.1080/14737167.2019.1637735] [PMID: 31248303]
[7]
Dilokthornsakul P, Thomas D, Brown L, Chaiyakunapruk N. Interpreting Pharmacoeconomic Findings. Clinical Pharmacy Education, Practice and Research 2019; pp. 277-87.
[http://dx.doi.org/10.1016/B978-0-12-814276-9.00019-2]
[8]
O’Brien GL, O’Mahony C, Cooke K, et al. Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. Clin Breast Cancer 2019; 19(3): e440-51.
[http://dx.doi.org/10.1016/j.clbc.2019.01.011] [PMID: 30853347]
[9]
Vinaykumar M, Venkatesh MP. Comparison of regulatory requirements for filing of generic drug product in USA and China. J Pharma Sci Res 2019; 11(6): 2426-36.
[10]
Franchise India How Pradhan Mantri Janaushadhi Pariyojana is affecting the healthcare industry. Available from: https://www.franchiseindia.com/wellness/how-pradhanmantri-janaushadhi-pariyojana-is-affecting-the-healthcare-industry
[11]
Mukherjee K. A cost analysis of the Jan Aushadhi scheme in India. Int J Health Policy Manag 2017; 6(5): 253-6.
[http://dx.doi.org/10.15171/ijhpm.2017.02] [PMID: 28812812]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy